A treatment-related increase in benign thyroid C-cell adenomas was seen in males in 0.25 and 0.75 mg/kg/day liraglutide groups with incidences of 12%, 16%, 42%, and 46% and in all female liraglutide-treated groups with incidences of 10%, 27%, 33%, and 56% in 0 (control), 0.075, 0.25, and 0.75 mg/kg/day groups, respectively
Some patients benefit from continuous therapy to prevent weight regain, since appetite-regulating hormones often rebound after stopping GLP-1 medications
Does the Precision Peptide Genetic Test tell me about glutathione metabolism
If any adverse effects occur, contact a healthcare provider immediately
This is the most common side effect, affecting a significant percentage of users
For microdosing, lower concentrations are almost always better